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Background and aims: To specify the prevalence of patients diagnosed with CF at age of 60 year-old and
to analyze their characteristics.
Patients and methods: Observational study of CF patients which were diagnosed at age 60 year-old. The
analyzed variables were: age, sex, nationality, lung function parameters, conditions present at diagnosis,
microbiological characteristics and genetic findings.
Results: eight patients were included. 7 patients were female (87.5%) with a mean age of 70.6 years
(median 71.5 years, range 60e78 years). The most important findings were: sweat test >60 mEq/l;
heterozygotes F508del; bronchiectasis in CT; methicillin-sensitive Staphylococcus aureus (50%) in sputum.
The most patients presented a normal or mild obstructive lung function.
Conclusions: CF must also be considered a disease diagnosed in adulthood, incorporating the sweat test
within the usual techniques of differential diagnosis in patients with different diseases associated with
CF, because genetic counselling is esencial.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Until recently, cystic fibrosis (CF) had been considered a child-
hood disease. Therapeutic advances and specialist units have
contributed towards this disease ceasing to be lethal in childhood
[1e3]. However, although current survival time can exceed 40
years, mostly in the case of patients from pediatric units, a diag-
nosis at over 40 years of age is still unusual, but the possibility of
diagnosis at over 60 years of age still exists [4,5]. Awareness of the
clinical characteristics of patients diagnosed at advanced ages could
be important in order to consider CF in adults of 60 years, since few
studies have been carried out so far. Diagnosis of CF is important
because it implies a prognosis and provision of appropriate treat-
ment, not to mention genetic counselling in families [1,4].
As a result we propose, as the main objective of our study, to
look into the percentage of CF patients diagnosed at over 60 years of
age. We would also analyze the reasons for which these patients
were referred to CF Units, their most common clinicald Bronchiectasis, Pulmonary
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the future, to understand that the age of the patient need not be a
limiting factor for the diagnosis of CF.
2. Patients and method
An observational, cross-sectional and descriptive study of pa-
tients older than 60 years and diagnosed with CF at the multidis-
ciplinary Units of Madrid Community (university hospitals La Paz,
Ramon y Cajal, Doce de Octubre, La Princesa and Ni~no Jesús) and
university hospital La Fe of Valencia was carried out between 1st of
March and 31st of May 2012 [4].
The genetic, microbiological, demographic and clinical charac-
teristics of each individual were analyzed. The CF diagnosis was
established in accordance with international guidelines [6,7].
All patients underwent a genetic study involving 47 mutations in
each simpleusing the test Inmunogenetics®, InnolipaCF-17, CF-19and
DeletionsCFTRþ6and itwasexpanded if themutationwasunknown.
At the time of writing, the genetic study was pending completion.
The lung function parameters studied were: forced vital ca-
pacity (FVC) in milliliters and percentage of predicted (ppFVC),
forced expiratory volume in one second (FEV1) in milliliters and
percentage of predicted (ppFEV1) and FEV1/FVC relation. Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic characteristics.
Clinical and demographic characteristics N ¼ 8 % Median Range
Gender (females/males) 7/1 87.5%/12.5%






Pancreatic insufficiency 2 25%
Rheumatoid arthritis 1 12.5%
Familiar history of CF 0 0%
2 or more pathologies at diagnosis 3 37.5%
Table 3
Pulmonary function.
Mean (n ¼ 8) Median Standard deviation Range
FEV1 (litres)a 1.790 1.880 0.430 (1.15e2.30)
FEV1 (%) 89.33% 94%% 29.11 (42e128)
FVC (litres)b 1.577 1.510 0.650 (0.8e2.60)
FVC (%) 83.3% 89% 38.8 (30e138)
FEV1/FVC 70.05% 74.5% 17.73 (43e87)
a FVC: forced vital capacity.
b FEV1: forced expiratory volume in one second.
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analyzed, taking the microbiological data of bacteria, mycobacteria
and fungi. These variables were studied at the time of data collec-
tion (or the closest possible).
Statistical analysis was performed using SPSS version 22.0 sta-
tistics. Quantitative variables were expressed as median and
interquartile range. The qualitative variables were expressed as
number of patients and their percentage.
Data was taken from the medical records of each patient. The
study followed the ethical standards of research of the Centers.
3. Results
Eight patients60 years-oldwere includedwithin 89 diagnosed
at18 years-old (8.9%) in ourmonographic CF Units, and 1.3% of the
total patients treated in these Units. Seven patients were women
(87.5%) and one male (12.5%) with a mean age of 70.6 (median 71.5
(60e78)) years-old. 7 patients (87.5%) were Spanish and the
remaining one was a citizen of Ecuador (Table 1).
The sweat test permitted the diagnosis of all patients studied
and the most frequently detected mutation was delF508/delF508
(p.Phe508X). In three cases, we can find mutations whose fre-
quency are less than 1.5%.
The clinical finding at the diagnosis time in all patients was the
presence of bronchiectasis, principal reason which motivated the
study of CF in this subgroup of patients older than 60 years-old. In
addition, pancreatic insufficiency was observed in 2 patients (25%)
at the time of diagnosis (Table 1).
The most frequent colonizing microorganism was meticilline
sensitive Staphylococcus aureus (MSSA) in 4 out of 8 patients (50%)
(Table 2).
Regarding the respiratory function parameters studied, the re-
sults showed that most patients had normal lung function or mild
obstructive ventilatory impairment (Table 3).
4. Discussion





No colonization 2 25%
Pseudomonas aeruginosa 1 12.5%
MRSAa 0 0%
MSSAb 4 50%
Haemophilus Influenzae 0 0%
2 or more (Stenotrophomona þ Mycobacterium avium
intracelulare)
1 12.5%
a MRSA: methicillin-resistant Staphilococcus aureus.
b MSSA: methicillin-sensitive Staphilococcus aureus.the diagnosis was 6 months-old, although 90% of the patients were
diagnosed at eight years of age [3,8]. The peculiarity of our study is
that patients were diagnosed at ages when many units no longer
consider this disease as likely, so it is rare that even a sweat test is
applied.
In other European series, which cases with suspected diffuse
bronchiectasis were studied, the incidence of CF was 7.6%, with an
average age of 31 (18e56) years-old. No patient exceeded 60 years-
old, as in our series [6]. In our Units, the most part of the patients
presented pancreatic sufficiency and only two of them had
pancreatic insufficiency at the time of diagnosis, similar to other
studies [2,3,5,9].
Among our patients, MSSA bronchial infection was the most
frequent, being the P. aeruginosa bronchial infection, the second
one in frequency (12.5%). The chronic bronchial infections and
bronchiectasis were the most typical pulmonary complications.
Our patients have a mean ppFEV1 of 89%, in contrast to other
series, in which the estimated ppFEV1 was lower [6,9,10]. Perhaps
this is due to the patients being firstly diagnosed with other dis-
eases, like asthma or COPD, so they were “misdiagnosed and
wrongly treated” for many years [5,6].
Another possible explanation could be that the patients who are
diagnosed at above 40 years of age, would be carriers of mutations
considered mild or of low risk, with predominantly negative or
borderline sweat tests, which would be associated with better
prognosis [11]. In these cases, other diagnostic techniques should
be considered, such as the study of differential nasal potential,
especially in those with undetermined chloride ion concentration
values (40e60 mEq/L) or questionable genetic tests [11e14].
Other causes leading to diagnosis found in our study were male
sterility, allergic bronchopulmonary aspergillosis (ABPA) and
recurrent respiratory infections. None of our patients have recur-
rent pancreatitis, despite that being one of the most common
clinical manifestations and diagnostic suspicions in other series,
both children and adults with CF [7,15,16].
Thus, CF should also be considered a disease to be diagnosed in
adulthood, including the sweat test within the usual tests of dif-
ferential diagnosis in patients with diseases, such as bronchiectasis
or chronic bronchial infection of unknown etiology. It is important
C. Prados et al. / Respiratory Medicine Case Reports 21 (2017) 49e51 51that diagnosis be made because this disease involves an indis-
pensable genetic counselling procedure in their families.
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